Survival after pulmonary metastasectomy for relapsed osteosarcoma
- PMID: 33349447
- DOI: 10.1016/j.jtcvs.2020.10.137
Survival after pulmonary metastasectomy for relapsed osteosarcoma
Abstract
Objectives: The purpose of this study was to evaluate the postrelapse survival of relapsed osteosarcoma with pulmonary metastases in patients who received pulmonary metastasectomy using intent to treat and propensity score analysis.
Methods: Patients with osteosarcoma who relapsed with pulmonary metastases between 2004 and 2018 who were treated in a hospital affiliated with a medical school were included. All the enrolled patients were evaluated as operable with assessment algorithm at the time of diagnosis of pulmonary relapse and intent to treat analysis was done. Multiple propensity score methods (eg, matching, stratification, covariate adjustment, and inverse probability of treatment weighting) were performed to balance confounding bias. Cox proportional hazards regression and the Kaplan-Meier method were used to evaluate patient survival.
Results: A total of 125 patients met the study criteria. Of these, 59 (47.2%) patients received pulmonary metastasectomy combined with chemotherapy and 66 (52.8%) received chemotherapy alone. The 2-year and 5-year postrelapse survival rate of metastasectomy group and nonmetastasectomy group were 68.4% versus 25.0% and 41.0% versus 0%, respectively. The median postrelapse survival was 24.9 versus 13.5 months, respectively. Pulmonary metastasectomy was independently associated with improved survival (hazard ratio, 0.185; 95% confidence interval, 0.103-0.330; P < .001). These results were confirmed by multiple propensity score analyses. Further stratified analysis revealed that the survival advantage associated with metastasectomy was not significant in patients with metastases involving ≥3 lung lobes and patients with very high pretreatment serum alkaline phosphatase (more than twice the upper limit).
Conclusions: Pulmonary metastasectomy is associated with improved survival in patients with recurrent osteosarcoma.
Keywords: metastasectomy; osteosarcoma; propensity score analysis; pulmonary metastases; relapse.
Copyright © 2020 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.
Comment in
-
Commentary: The best outcomes for pulmonary metastasectomy come from picking the right patients.J Thorac Cardiovasc Surg. 2022 Feb;163(2):483-484. doi: 10.1016/j.jtcvs.2020.11.014. Epub 2020 Nov 6. J Thorac Cardiovasc Surg. 2022. PMID: 33309287 Free PMC article. No abstract available.
-
Commentary: Proving the benefit of pulmonary metastasectomy for relapsed osteosarcoma-to the next hard target?J Thorac Cardiovasc Surg. 2022 Feb;163(2):480-481. doi: 10.1016/j.jtcvs.2020.11.043. Epub 2020 Nov 19. J Thorac Cardiovasc Surg. 2022. PMID: 33334598 No abstract available.
-
Commentary: Upping our game.J Thorac Cardiovasc Surg. 2022 Feb;163(2):481-482. doi: 10.1016/j.jtcvs.2020.11.086. Epub 2020 Nov 28. J Thorac Cardiovasc Surg. 2022. PMID: 33419535 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous